PDCD1 and urothelial carcinoma: Also, in non-small cell lung cancer and urothelial carcinoma under anti-PD-1 ICB, decreased M-MDSC frequencies were associated with better clinical responses.44 45 The involvement of PD-1 blockade in differentiation and development of M-MDSCs in humans is still unknown.